Journal of psychosocial oncology · 2026
Depression as a potential early indicator of pancreatic cancer: a systematic review of prevalence, mechanisms, and temporal associations.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Frangie Machado Melissa, Masoumi Niloofar, Azari Leila, Centrella Megan, Mukenschnabl Kami, Lin Yu Chen, Hodul Pamela, Islam Jessica Y, Turner Kea, Alishahi Tabriz Amir
Аннотация
BACKGROUND: Pancreatic cancer (PC) remains one of the most lethal malignancies, with a five-year survival rate of only 12%, largely due to late diagnosis. Depression is frequently reported in PC and may precede its onset, yet underlying mechanisms remain unclear.
AIMS: This systematic review examined (1) the prevalence of depression in PC, (2) potential psychological, clinical, and biological mechanisms, and (3) the temporality of depressive symptoms relative to PC diagnosis.
METHODS: Following PRISMA guidelines, EMBASE, MEDLINE, Web of Science, and Cochrane were searched through February 2025 (PROSPERO: CRD42022378830). Studies including adults with PC assessing depression or related biomarkers were analyzed.
RESULTS: Twenty-six studies met inclusion criteria. Depression prevalence ranged 3.5-51.8%. Six studies reported depressive symptoms often preceding diagnosis by 3-6 months. Biomarker studies identified elevated IL-6, CRP, and kynurenine-tryptophan pathway alterations.
CONCLUSIONS: Depression may represent a paraneoplastic or early manifestation of PC. Further prospective, mechanistic studies are warranted.
AIMS: This systematic review examined (1) the prevalence of depression in PC, (2) potential psychological, clinical, and biological mechanisms, and (3) the temporality of depressive symptoms relative to PC diagnosis.
METHODS: Following PRISMA guidelines, EMBASE, MEDLINE, Web of Science, and Cochrane were searched through February 2025 (PROSPERO: CRD42022378830). Studies including adults with PC assessing depression or related biomarkers were analyzed.
RESULTS: Twenty-six studies met inclusion criteria. Depression prevalence ranged 3.5-51.8%. Six studies reported depressive symptoms often preceding diagnosis by 3-6 months. Biomarker studies identified elevated IL-6, CRP, and kynurenine-tryptophan pathway alterations.
CONCLUSIONS: Depression may represent a paraneoplastic or early manifestation of PC. Further prospective, mechanistic studies are warranted.